Assessment of joint bleeding and target joints in patients with severe or moderately severe hemophilia B (factor IX ≤2%) receiving prophylaxis with rIX-FP in the PROLONG-9FP clinical trial program

  1. Laws, H.-J.
  2. Fukutake, K.
  3. Lopez-Fernandez, M.F.
  4. Li, Y.
  5. Seifert, W.
  6. Tagliaferri, A.
Revista:
European Journal of Haematology

ISSN: 1600-0609 0902-4441

Ano de publicación: 2023

Volume: 111

Número: 2

Páxinas: 293-299

Tipo: Artigo

DOI: 10.1111/EJH.14010 GOOGLE SCHOLAR lock_openAcceso aberto editor

Obxectivos de Desenvolvemento Sustentable